Loretta Nastoupil, MD
Hematology & Oncology · Houston, TXNPI 1407048630
Payments from drug & device makers
Across 457 payments — averaging $40,003 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$7.8M
- Bristol Myers Squibb$2.7M
- Gilead$2.6M
- Genentech, Inc.$2.6M
- Merck$1.1M
- Janssen Research & Development, LLC$325K
- plus $1.1M from 24 others
Across 22 payments — averaging $7981.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orphai Therapeutics Inc.$162K
- F. Hoffmann-la Roche AG$7K
- Pfizer$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Novartis$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $7,799,186 |
| Bristol Myers Squibb | 88 | $2,729,965 |
| Gilead(2 entities) | 81 | $2,623,003 |
| Genentech, Inc. | 60 | $2,593,280 |
| Merck | 14 | $1,134,683 |
| Janssen Research & Development, LLC | 17 | $324,800 |
| Beigene, Ltd. | 11 | $287,621 |
| Epizyme, Inc. | 33 | $226,798 |
| Novartis | 21 | $206,346 |
| E.r. Squibb & Sons, L.L.C. | 17 | $144,043 |
| Hoffmann-la Roche Limited | 7 | $104,173 |
| Janssen Global Services, LLC | 8 | $20,220 |
| F. Hoffmann-la Roche AG | 20 | $17,882 |
| Bayer | 3 | $10,780 |
| AstraZeneca | 5 | $8,939 |
| Genentech USA, Inc. | 11 | $8,903 |
| Pfizer | 1 | $8,820 |
| Incyte Corporation | 7 | $8,552 |
| AbbVie | 6 | $5,441 |
| Genmab U.S., Inc. | 7 | $3,346 |
| Regeneron | 4 | $3,112 |
| ADC Therapeutics America, Inc. | 4 | $2,695 |
| Morphosys, US Inc. | 1 | $2,655 |
| Beigene USA, Inc. | 2 | $2,625 |
| Eisai CO., LTD. | 1 | $1,691 |
| Daiichi Sankyo Inc. | 4 | $825 |
| Astrazeneca UK Limited | 2 | $745 |
| Seagen Inc. | 3 | $170 |
| TG Therapeutics, Inc. | 2 | $169 |
| Janssen Scientific Affairs, LLC | 1 | $56 |
How this compares
$18,281,523 in reported general payments places this provider in the 95th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Houston
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Christopher FlowersHouston$17.2M
- Philip ThompsonHouston$13.6M
- Naval DaverHouston$13.6M
- Ghayas IssaHouston$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.